Medical Experts Allowed In Pfizer Securities Suit

Law360, New York (March 23, 2010, 2:47 PM EDT) -- A federal judge has allowed Pfizer Inc. and a class of plaintiffs suing it for securities fraud in connection with the marketing of its anti-inflammatory drugs Celebrex and Bextra to introduce medical experts, denying both sides' motions to exclude each other’s experts.

Judge Laura Taylor Swain of the U.S. District Court for the Southern District of New York ruled Monday that the Pfizer experts and the six plaintiffs' experts whose admissibility had been challenged met the standard for admissibility set out in Daubert v. Merrell Dow...
To view the full article, register now.